| Name | Title | Contact Details |
|---|
Phycotransgenics, LLC is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation.
ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer`s disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer`s disease, but other Neurodegenerative Conditions such as Huntington`s disease, Parkinson`s disease and MS, and recover quality of life for those patients and their families.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.